Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Adult female participants with histological diagnosis of breast cancer
Any type of chemotherapy planned for greater than or equal to (\>/=) 9 weeks
Hemoglobin level less than (\<) 11 grams per deciliter (g/dL)
Participants able to receive iron supplement, if necessary
You may not be if
Known or suspected contraindications to epoetin beta
Pregnancy or lactation period
Diagnosis of anemia only due to iron-deficiency
Diagnosis of thalasemic syndromes
Epilepsy and/or cerebral metastasis
Blood transfusion or treatment with any erythropoietic factor within 4 weeks before study start
Clareo Health | A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
